In vitro susceptibility studies of 246 clinical isolates demonstrated that this antibiotic was effective against Group A beta hemolytic streptococci, alpha hemolytic streptococci, S. pneumoniae, both penicillinase producing and nonpenicillinase producing Staphylococci, Klebsiella pneumoniae, and Proteus mirabilis. Cephalothin susceptible E. coii were also susceptible to cefaclor. Pseudomonas aeruginosa, Serratia sp., Enterobacter Sp., and Streptococcus faecalis were uniformly resistant to cefaclor. The efficacy and safety of this antibiotic were studied in 27 patients with urinary tract, soft tissue, and respiratory infections. Patients with urinary tract infections became abacteriuric after 48 hours. Patients with soft tissue infections responded well within the first week of therapy, and throat cultures of patients with tonsillitis were negative ten days and six weeks after treatment. The drug was well tolerated, and no significant adverse effect was noted.
Kiani, Daria; Madhavan, Tom; Burch, Keith; Pohlod, Don; Fisher, Evelyn; and Quinn, Edward L.
"In Vitro and Clinical Studies of Cefaclor, A New Cephalosporin,"
Henry Ford Hospital Medical Journal
: Vol. 26
Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol26/iss4/3